DACOGEN ® is a DNA hypomethylating agent currently approved for the treatment of myelodysplastic syndromes (MDS) in more than 35 countries worldwide including key markets such as the United States, Brazil, China, India, Korea, Russia and Turkey.. with acute myeloid leukemia, chronic myelogenous leukemia, and solid tumors, in addition to developing alternative dosing regimens for patients with MDS." "This approval is a significant milestone for SuperGen.. September 28, 2012 — The European Commission has approved the hypomethylating agent decitabine (Dacogen, Astex/Eisai) for acute myeloid leukemia (AML) in adults 65 years and older, Astex . Dacogen is already approved in the USA for the treatment of patients with myelodysplastic syndromes. Astex Pharmaceuticals licensed the drug to Eisai which in turn sold rights outside of North America to Johnson and Johnson and the latter's Janssen unit submitted a file for Dacogen as a treatment for AML in Europe in May last year.. . .